Comparison
3 Methylglutaconic Aciduria C3696376 vs 17p11 2 Microduplication Syndrome C2931246
Clinical comparison between 3 Methylglutaconic Aciduria and 17p11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria C3696376
A metabolic disorder causing abnormal acid buildup affecting multiple body systems including the brain. Severity varies widely among affected individuals. Care focuses on symptom management and metabolic support.
17p11 2 Microduplication Syndrome C2931246
A chromosomal condition involving duplication on chromosome 17, related to Potocki-Lupski syndrome. Features often include developmental delays, learning challenges, and distinctive facial features.
6 comparison axes
Onset
3 Methylglutaconic Aciduria C3696376
0-10
17p11 2 Microduplication Syndrome C2931246
0-null
Onset patterns differ
Severity
3 Methylglutaconic Aciduria C3696376
severe
17p11 2 Microduplication Syndrome C2931246
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria C3696376
Chronic
17p11 2 Microduplication Syndrome C2931246
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria C3696376
No
17p11 2 Microduplication Syndrome C2931246
No
Different transmission
Body System
3 Methylglutaconic Aciduria C3696376
metabolic
17p11 2 Microduplication Syndrome C2931246
congenital
Same/different system
Category
3 Methylglutaconic Aciduria C3696376
metabolic
17p11 2 Microduplication Syndrome C2931246
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-C3696376 and 17p11-2-microduplication-syndrome-C2931246 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria C3696376 | 17p11 2 Microduplication Syndrome C2931246 | Discriminating power |
|---|---|---|---|
| Metabolic decompensation | May include episodic illness with neurologic change; pattern varies widely. | Not a typical defining feature of the chromosomal condition. | High |
| Developmental profile | Neurologic involvement may occur, but presentation is heterogeneous. | Developmental delay and learning challenges are commonly described. | Moderate |
| Physical features | No single facial pattern is established by the supplied data. | Distinctive facial features are often reported. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria C3696376 when
Unexplained neurologic or multisystem illness
A metabolic disorder is more plausible when symptoms suggest abnormal acid accumulation.
Moderate
Abnormal organic-acid result
The named aciduria should be considered, but the result needs clinician interpretation.
High
Acute metabolic concern
Supportive metabolic evaluation is prioritized over a chromosomal explanation.
Moderate
Choose 17p11 2 Microduplication Syndrome C2931246 when
Congenital developmental delay
A chromosomal duplication better fits early developmental and learning concerns.
Moderate
Characteristic facial findings
Reported facial features support consideration of 17p11.2 microduplication.
Moderate
Positive chromosomal microarray
A confirmed 17p11.2 duplication supports this diagnosis after specialist review.
High
How key tests differ
| Test | 3 Methylglutaconic Aciduria C3696376 | 17p11 2 Microduplication Syndrome C2931246 | Interpretation |
|---|---|---|---|
| Urine organic acids | May show elevated 3-methylglutaconic acid; exact cutoff not supplied. | No characteristic organic-acid abnormality is established. | An abnormal result is not by itself a complete diagnosis. |
| Chromosomal microarray | Not expected to identify the metabolic condition. | May detect duplication at 17p11.2. | Genetic confirmation requires laboratory and clinical correlation. |
| Neurologic assessment | May reveal variable brain or neurologic involvement. | Often documents developmental delay or learning difficulty. | Findings overlap and cannot reliably separate the conditions alone. |
Prognosis comparison
3 Methylglutaconic Aciduria C3696376
- Outcome
- Chronic course with widely variable severity; exact outcomes are not established.
- Factors
- Extent of neurologic and metabolic involvement may influence course.
17p11 2 Microduplication Syndrome C2931246
- Outcome
- Generally described as moderate and chronic, but individual outcomes vary.
- Factors
- Developmental and learning needs influence long-term support.
Time frame: Often recognized in childhood; lifelong implications may occur.
Diagnosis confirmation, associated findings, and access to supportive care matter.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic impairment | Possible and potentially severe, with wide individual variation. Developmental and learning effects are commonly described. Severity and permanence are not established from the supplied data. |
| Metabolic crisis | A recognized concern requiring symptom-focused metabolic support. Not described as a typical complication. No treatment doses or protocols are provided. |
| Multisystem effects | Multiple body systems, including the brain, may be affected. Main described effects are developmental, learning, and facial. Additional complications should not be assumed without evaluation. |
Patient education highlights
- HighDifferent causes
One condition is metabolic; the other is a chromosomal duplication. They are not interchangeable diagnoses.
- HighSpecialist follow-up
A clinician should interpret tests and coordinate metabolic or genetics care as appropriate.
- MediumVariable course
Features and severity vary, especially in 3-methylglutaconic aciduria; avoid predictions from limited information.